Fates CollideFates Collide🃏All Omastar cards
Ask about Omastar
Omastar #18 Pokémon card from Fates Collide

Omastar 18/124

Fates Collide

👁 Watch📊 Add to portfolioFree — no card required to register.
Find this card on eBay

Affiliate link · we may earn commission

Omastar #18 from Fates Collide currently trades at $0.41 raw, with PSA 10 copies reaching $33.37 — a 81.4x grade premium.
Current Prices (USD)
Ungraded
$0.41
PSA 7
$5.50
PSA 8
$5.50
PSA 9
$11.84
PSA 10
$33.37
ACE 10
BGS 10 Black
$215.00
CGC 10 Pristine
$36.00
Compare on eBay

Affiliate link · we may earn commission

Quick price facts

Omastar 18/124 from Fates Collide has a current raw market value of $0.41.

Current raw value
$0.41
PSA 9 value
$11.84
PSA 10 value
$33.37
View all cards from Fates Collide
Collector Intel
81.4x
Raw → PSA 10
High-risk grade
28.9x
Raw → PSA 9
Grade multiplier

Calculated from price history, PSA population data, and market trends. Not financial advice.

Grading Calculator

Based on PSA Standard tier (~$25 USD). Assumes a perfect PSA 10 result — actual outcome depends on card condition.

⚠️ High-variance grade. PSA 10 is 81x the raw price. The expected value accounts for the realistic probability.
$0
Buy Raw
~$25
Grading Fee
PSA Standard
$33
PSA 10 Value
+$8
Best Case (PSA 10)
if you pull a 10
Grade Multiples vs Raw
PSA 9$1228.9x raw
PSA 10$3381.4x raw

Frequently asked questions

How much is Omastar #18 from Fates Collide worth?+
Omastar #18 from Fates Collide is currently worth Raw: $0.41, PSA 9: $11.84, PSA 10: $33.37 based on recent sold listings. Prices update daily from real eBay sales.
Is Omastar #18 worth grading?+
The PSA 10 price of $33.37 is 81.4× the raw price of $0.41. After a ~$25 grading fee, a PSA 10 result would net approximately $32.96 — assuming the card grades a 10.
Where do PokePrices Omastar #18 prices come from?+
Prices are tracked nightly from real sold listings on PriceCharting (raw, PSA 9 and PSA 10). PSA population data is sourced from PSA's public reports. We do not use asking prices — only confirmed sales.